- Home
- RS vs IKT Comparison
RS vs IKT Comparison
Compare RS & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RS
- IKT
- Stock Information
- Founded
- RS 1939
- IKT 2008
- Country
- RS United States
- IKT United States
- Employees
- RS N/A
- IKT N/A
- Industry
- RS Metal Fabrications
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- RS Industrials
- IKT Health Care
- Exchange
- RS Nasdaq
- IKT Nasdaq
- Market Cap
- RS 15.5B
- IKT 159.2M
- IPO Year
- RS 1994
- IKT 2020
- Fundamental
- Price
- RS $267.76
- IKT $3.03
- Analyst Decision
- RS Hold
- IKT Strong Buy
- Analyst Count
- RS 5
- IKT 2
- Target Price
- RS $344.00
- IKT $6.50
- AVG Volume (30 Days)
- RS 515.5K
- IKT 451.1K
- Earning Date
- RS 02-13-2025
- IKT 11-14-2024
- Dividend Yield
- RS 1.63%
- IKT N/A
- EPS Growth
- RS N/A
- IKT N/A
- EPS
- RS 18.25
- IKT N/A
- Revenue
- RS $14,045,700,000.00
- IKT $1.00
- Revenue This Year
- RS N/A
- IKT N/A
- Revenue Next Year
- RS $1.48
- IKT N/A
- P/E Ratio
- RS $14.78
- IKT N/A
- Revenue Growth
- RS N/A
- IKT N/A
- 52 Week Low
- RS $256.98
- IKT $1.12
- 52 Week High
- RS $342.20
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- RS 27.70
- IKT 51.12
- Support Level
- RS $256.98
- IKT $2.90
- Resistance Level
- RS $273.39
- IKT $3.12
- Average True Range (ATR)
- RS 6.95
- IKT 0.37
- MACD
- RS -2.30
- IKT -0.07
- Stochastic Oscillator
- RS 21.56
- IKT 9.56
About RS Reliance Steel & Aluminum Co. (DE)
Reliance Inc is a diversified metal solutions provider and metals service center company. It provides value-added metals processing services and distributes.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.